Eli Lilly Reports Positive Phase 1b Verve-102 Study Results

Eli Lilly (LLY) announced positive interim results from its Phase 1b Heart-2 study for the investigational in vivo base editing medicine, Verve-102. The drug demonstrated dose-dependent reductions of up to 88% in PCSK9 and LDL-C levels with durability observed over 18 months.

By Jeff Lewis Fri, May 29, 2026 at 9:04 AM GMT+3 2 min read · Yahoo Finance · May 29, 2026, 06:04 UTC

Eli Lilly Reports Positive Phase 1b Verve-102 Study Results

Tickers: $LLY

Topics: cardiovascular health gene-editing pharmaceuticals

Read the full article at Yahoo Finance

More World news

Spout Finance Integrates Ondo Stocks to Enable Interest-Free USDC Borrowing via Covered Calls PR Newswire · November 12, 2026, 14:30 UTC
Deswell Industries Announces Semi-Annual Dividend of $0.10 Per Share Seeking Alpha · November 12, 2026, 14:24 UTC
Nvidia Shares Plunge Following Announcement of CEO Jensen Huang's Resignation Seeking Alpha · November 12, 2026, 14:24 UTC
Archer Aviation Enters Multi-Year Partnership with Formula One Seeking Alpha · November 12, 2026, 14:16 UTC
Edgewell Personal Care Announces Quarterly Dividend of $0.15 Per Share Seeking Alpha · November 12, 2026, 14:16 UTC
Hudbay Minerals Announces Quarterly Dividend of CAD 0.01 Per Share Seeking Alpha · November 12, 2026, 14:16 UTC
Warby Parker Unveils AI-Powered Intelligent Eyewear Collection in Partnership with Google and Samsung Seeking Alpha · November 12, 2026, 14:17 UTC
Where Food Comes From Reports Q3 Revenue Growth and Improved Gross Margins Seeking Alpha · November 12, 2026, 14:17 UTC
Medical Care Technologies Inc. Reports Q3 Revenue Growth and Significant Net Income Increase Seeking Alpha · November 12, 2026, 14:17 UTC
Digi International Reports Record Fiscal 2026 Results and Announces Acquisition of Disruptive Technologies Motley Fool · November 12, 2026, 14:15 UTC